Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Dec 10;39(35):3997-3998.
doi: 10.1200/JCO.21.02150. Epub 2021 Oct 8.

Reply to K. Takada et al

Noha Sharafeldin  1 , Benjamin Bates  1 , Qianqian Song  1 , Vithal Madhira  1 , Yu Raymond Shao  1 , Feifan Liu  1 , Timothy Bergquist  1 , Jing Su  1 , Umit Topaloglu  1
Affiliations
Comment

Reply to K. Takada et al

Noha Sharafeldin et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Benjamin BatesStock and Other Ownership Interests: Pfizer (I) Yu Raymond ShaoEmployment: GlaxoSmithKline (I), Suzhou Kintor Pharmaceuticals (I) Feifan LiuStock and Other Ownership Interests: Pfizer Timothy BergquistResearch Funding: Celgene (Inst) Umit TopalogluStock and Other Ownership Interests: CareDirectionsNo other potential conflicts of interest were reported.

Comment on

References

    1. Takada K, Takamori S, Miura N, et al. Reasons to consider the COVID-19 vaccination status of cancer patients when analyzing their COVID-19 outcomes. J Clin Oncol. 2021;39:3996. - PMC - PubMed
    1. Agha M, Blake M, Chilleo C, et al. Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients. medRxiv. doi: 10.1101/2021.04.06.21254949. - DOI - PMC - PubMed
    1. Monin L, Laing AG, Munoz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: Interim analysis of a prospective observational study Lancet Oncol 22765–7782021 - PMC - PubMed
    1. Sharafeldin N, Bates B, Song Q, et al. Outcomes of COVID-19 in patients with cancer: Report from the National COVID Cohort Collaborative (N3C) J Clin Oncol 392232–22462021 - PMC - PubMed
    1. Haendel MA, Chute CG, Bennett TD, et al. The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment J Am Med Inform Assoc 28427–4432021 - PMC - PubMed